Amphastar Pharma (AMPH) Tops Q3 EPS by 45c

Amphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $1.15, $0.45 better than the analyst estimate of $0.70. Revenue for the quarter came in at $180.6 million versus the consensus estimate of $174.63 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus